Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 2
1997 1
2000 1
2003 1
2004 4
2005 1
2006 4
2007 6
2008 4
2009 2
2010 1
2011 1
2012 3
2014 1
2015 2
2016 2
2017 5
2018 4
2019 5
2020 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.
Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J. Lim JS, et al. Among authors: kapoun am. Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10. Nature. 2017. PMID: 28489825 Free PMC article.
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC. Jimeno A, et al. Among authors: kapoun am. Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19. Invest New Drugs. 2019. PMID: 30229512 Clinical Trial.
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ. Davis SL, et al. Among authors: kapoun am. Invest New Drugs. 2020 Jun;38(3):821-830. doi: 10.1007/s10637-019-00824-1. Epub 2019 Jul 23. Invest New Drugs. 2020. PMID: 31338636 Free PMC article. Clinical Trial.
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Ferrarotto R, et al. Among authors: kapoun am. J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870570 Free PMC article.
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM. Hu ZI, et al. Among authors: kapoun am. Cancer Med. 2019 Sep;8(11):5148-5157. doi: 10.1002/cam4.2425. Epub 2019 Jul 26. Cancer Med. 2019. PMID: 31347292 Free PMC article. Clinical Trial.
48 results